Ma Hong

Dr. Ma was the director of clinical operations at Endocyte, Inc. (NASDAQ: ECYT) from June 2012 to July 2014. He then worked as a temporary employee at Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) from September 2014 to December 2014 and served as the director of clinical development from December 2014 to May 2016. Dr. Ma served as the senior medical director at Immatics Biotechnologies GmbH (NASDAQ: IMTX) from May 2016 to August 2018.

Dr. Ma obtained his bachelor’s degree in clinical medicine and his master’s degree in cancer pathophysiology from Central South University, formerly known as Hunan Medical University), the PRC, in July 1994 and July 1997, respectively. He received his master’s degree in business administration from University of Georgia, the United States, in May 2005. Dr. Ma has been a member of the American Society of Clinical Oncology since 2011. He has also been a member of the American Society of Hematology since 2016.